Annovis Bio (NYSE: ANVS)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-02 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.070 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Annovis Bio (NYSE: ANVS) through any online brokerage.
Other companies in Annovis Bio’s space includes: Alzamend Neuro (NASDAQ:ALZN), HOOKIPA Pharma (NASDAQ:HOOK), Ambrx Biopharma (NYSE:AMAM), Curis (NASDAQ:CRIS) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Annovis Bio (NYSE: ANVS) was reported by Ladenburg Thalmann on Monday, May 2, 2022. The analyst firm set a price target for 37.00 expecting ANVS to rise to within 12 months (a possible 197.19% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Annovis Bio (NYSE: ANVS) is $12.4501 last updated August 17, 2022, 7:57 PM UTC.
There are no upcoming dividends for Annovis Bio.
Annovis Bio’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for Annovis Bio.
Annovis Bio is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.